Rhythm Pharmaceuticals (RYTM) EVP Yann Mazabraud awarded 35,000 stock options

Rhea-AI Filing Summary

Rhythm Pharmaceuticals executive Yann Mazabraud received a grant of 35,000 stock options on March 2, 2026. The options carry an exercise right to buy company stock at a set price and were awarded at no cost. They vest in 16 substantially equal installments, each after three full months of continued service to the company, tying the award to ongoing employment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazabraud Yann

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of International

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$94.94	03/02/2026		A		35,000		(1)	03/01/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The stock options were granted on March 2, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rhythm Pharmaceuticals (RYTM) report for Yann Mazabraud?

Rhythm Pharmaceuticals reported that EVP, Head of International Yann Mazabraud received a grant of 35,000 stock options on March 2, 2026. These derivative securities give him the right to buy company shares, subject to a multi-year vesting schedule based on continued service.

How many Rhythm Pharmaceuticals (RYTM) stock options were granted to Yann Mazabraud?

Yann Mazabraud was granted 35,000 stock options. Following this award, his direct derivative holdings from this grant total 35,000 options, which vest over time in 16 substantially equal installments tied to three-month service periods after the grant date.

At what price were the Rhythm Pharmaceuticals (RYTM) stock options granted to Yann Mazabraud?

The stock options were granted at a reported price of $0.00 per option. This reflects that they were an equity incentive award rather than a purchase, with value realized only if the options are exercised once vested and in the money.

What is the vesting schedule for Yann Mazabraud’s Rhythm Pharmaceuticals (RYTM) stock options?

The options vest in 16 substantially equal installments. Each installment becomes exercisable after Yann Mazabraud completes three full months of successive service following the March 2, 2026 grant date, creating a service-based vesting schedule extending over multiple years.

Does Yann Mazabraud hold these Rhythm Pharmaceuticals (RYTM) options directly or indirectly?

The filing states that Yann Mazabraud holds the 35,000 stock options directly. The ownership code is reported as “D” for direct ownership, and no footnotes indicate any trust, LLC, or other indirect holding structure for this specific award.

What type of security was granted to Yann Mazabraud by Rhythm Pharmaceuticals (RYTM)?

The award consists of “Stock Options (Right to Buy)” derivative securities. These options give Yann Mazabraud the contractual right to purchase Rhythm Pharmaceuticals common stock in the future once vested, aligning his compensation with potential long-term shareholder value.